WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Israel, Iran show restraint. But for how long?Kawhi Leonard will miss Game 1 for Los Angeles Clippers against Dallas MavericksREVEALED: The New York towns that STILL ban booze nine decades after end of prohibitionAngels third baseman Anthony Rendon placed on 10United escapes with shootout win after blowing threePaul Mescal is a splash hit... and that's before the heartCasey Mize throws 6 shutout innings for 1st win since 2021 as Tigers beat Twins 6Olivia Rodrigo shows off her abs in a bikini during sunny getaway8 shot, 2 men killed at a party in Memphis parkJimmy Vesey and Artemi Panarin lead Rangers to 4
2.3724s , 6491.0859375 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Planet Pulse news portal